TSX Venture: QPT
EDMONTON, April 8, 2013 /CNW/ - Quest PharmaTech Inc. (TSX-V: QPT)
("Quest" or the "Company"), a pharmaceutical company developing and
commercializing products for the treatment of cancer, announces that it
has recently signed an exclusive license agreement with University of
California at Los Angeles to develop and market anti-PSA IgE technology
for the treatment of cancer.
The technology was developed by Professor Manuel Penichet and Dr. Tracy
Daniels-Wells in collaboration with Dr. Christopher Nicodemus among
others. It covers the use of immunotherapeutic IgE in development for
treatment of patients with malignancies expressing the tumor-associated
antigen PSA, which is associated with prostate cancer.
Dr. Tracy Daniels-Wells will present promising preclinical results
obtained with the anti-PSA monoclonal IgE as a novel therapy for
prostate cancer in the upcoming AACR meeting in Washington D.C. on
April 9, 2013. The data demonstrate the potential ability of the novel
molecule to selectively open the circulation which may improve the
ability of cytotoxic therapy to reach cancers. At the same time, the
antibody can activate specific cellular immune responses directed
against PSA originating in the tumor. The presentation includes a
demonstration of antitumor activity in a PSA expressing tumor mouse
Quest is focusing its commercial efforts in the area of antibody
mediated cancer immunotherapy with both IgG and IgE products. Quest
holds numerous patents for the use of tumor associated monoclonal
antibodies as immune modulators. "Both IgG and IgE technologies are
complementary and provide a novel approach for enhancing the
effectiveness of chemotherapy while activating specific immunity to
fight the cancer" commented Dr. Madi R. Madiyalakan, CEO of the
The licensed technology platform includes three pending patent
applications. Under the license agreement, Quest is obligated to make
an upfront fee, milestone and royalty payments to UCLA on future
About Quest PharmaTech Inc.
Quest PharmaTech is a publicly traded; Canadian based clinical stage
company developing a portfolio of product candidates for the treatment
of cancer by combining immunotherapeutic antibodies with chemotherapy,
immune-adjuvants and photodynamic therapy. Quest has a body of clinical
experience and a new appreciation of the obstacles and potential of
combinatorial immunotherapeutic approaches to cancer by using either
immunoglobulin G or E as immune modulators to enhance tumor specific
immunity and clinical outcome.
The most advanced of its product candidates is oregovomab, an anti-CA125
monoclonal antibody, in combination with front-line chemotherapy for
the treatment of advanced ovarian cancer which is currently undergoing
a phase IIb clinical trial in 12 centers in Italy and the U.S. The
Company's MUC1 program that has already undergone a phase I clinical
trial has the potential to permit tumor specific immunization in more
than 70% of all cancers that kill. Quest is also conducting a phase I
clinical trial for the treatment of prostate cancer, with its
Neither TSX Venture Exchange nor its Regulation Services Provider (as
that term is defined in the policies of the TSX Venture Exchange)
accepts responsibility for the adequacy or accuracy of this release.
SOURCE: Quest PharmaTech Inc.
For further information:
Dr. Madi R. Madiyalakan, Chief Executive Officer, Quest PharmaTech Inc., Tel: (780) 448-1400 Ext. 204, Email: firstname.lastname@example.org, Internet: www.questpharmatech.com.